This wiki has undergone a migration to Confluence found Here
20170110 US Realm SC Call
Jump to navigation
Jump to search
back to US_Realm_Steering_Committee
back to US_Realm_Steering_Committee_Conference_Calls
| US Realm Steering Committee Call Agenda/Minutes Location: call 770-657-9270 using code 156896# |
Date: 2017-01-10 Time: 1 PM Eastern | ||
| Co-Chairs | Ed/Brett | Note taker(s) | Anne |
| Attendee / Name | |||||
| x | Calvin Beebe | Keith Boone | Regrets | Hans Buitendijk | |
| x | Lorraine Constable | x | Johnathan Coleman | x | Ed Hammond |
| x | Tony Julian | x | Paul Knapp | x | Austin Kreisler |
| x | Brett Marquard | Ken McCaslin | Nancy Orvis | ||
| Brian Pech | x | Wayne Kubick | Mark Roche | ||
| Sandra Stuart | . | Pat Van Dyke | x | Anne Wizauer | |
| x | Danielle Friend | x | Eric Haas | Regrets | Jenni Syed |
| Steve Posnak | . | David Susanto | x | Craig Parker | |
| Visitor/ Name | |||||
| x | Riki Merrick | x | Chris Johnson | ||
| no quorum definition | |||||
Agenda
Administrivia
- UPDATED US Realm Meeting Day/Time for San Antonio: Tuesday, 7:00 am, Blanco Room
- Agenda review
- Review notes from 20161206_US_Realm_SC_Call
- Review Items:
- Project Approval Request from the OO WG of the SSD-SD of Newborn Dried Blood Spot Screening Lab Order Component/ Implementation Guide
- Discussion:
- Payer community representation on US Realm Steering Committee
- Do we want to expand the scope of the FHIR US-Core? What is the process?
- What US Realm FHIR IGs are we tracking? (this should probably be a recurring agenda item)
- Who is providing coordination among those IGs?
- Do we want to develop a list of principles for developing US Realm FHIR IGs?
- Reuse us-core
- Follow us realm extension development process
- Quality criteria (see example SDWG use for C-CDA)
Minutes
- Meeting begins at 1:06 pm Eastern
- Ed reminds group of new meeting time in San Antonio
- Agenda review
- Review notes from 20161206_US_Realm_SC_Call
- Review Items:
- Project Approval Request from the OO WG of the SSD-SD of Newborn Dried Blood Spot Screening Lab Order Component/ Implementation Guide
- Riki reviews project. LOI will go through second ballot in May that will include this content. Ed: Why is this uniquely US? Lorraine: The underlying guide is US. Riki: Could be used elsewhere, but all the data elements are US-based. First objective is STU ballot in 2017May. ARB will also review. Further discussion over whether this can be used outside the US. Ed suggests we need to make the international community aware of the project.
- MOTION to approve: Austin/Paul
- VOTE: all in favor
- ACTION: Anne to add issue to WGM agenda
- Project Approval Request from the OO WG of the SSD-SD of Newborn Dried Blood Spot Screening Lab Order Component/ Implementation Guide
- Discussion:
- Payer community representation on US Realm Steering Committee
- Ed notes that the payer community would like Christol Green from Blue Cross Blue Shield to be part of the group as a representative.
- MOTION to add Christol Green to the US REalm Steering Committee: Paul/Johnathan
- VOTE: All in favor
- ACTION: Anne to add to group
- Do we want to expand the scope of the FHIR US-Core? What is the process?
- US core not published yet - will be published at the end of March. Don't have a process yet. Lorraine notes the repository project had a process. Johnathan: There are misunderstandings over what US core is. Ed agrees that the name is misleading. Paul: The scope of US realm stuff would be anything the US realm needs. Brett: Within the FHIR spec, there was a set of templates that have been renamed to US core. Brett's question is what do we do when someone wants to add to US core? How do we respond? Paul: We should fix the name first. Johnathan: Renaming from DAF was a good idea but doesn't reflect what it is. Brett: There was a lot of effort to rename it. Johnathan: We've got to be able to communicate what it is before we think about processes. Ed: We need a name without confusion.
- ACTION: Anne to add US Core definition to WGM agenda
- What US Realm FHIR IGs are we tracking? (this should probably be a recurring agenda item)
- What is our role in tracking? Do we approve and then let them go? Austin: This body has a mandate to be more than a clearing house. Ed: Are we really a TSC for the US? Discussion over relationship with TSC and risk of overlap. Austin: If we act as the US Affiliate, then there is overlap. This is the workaround in the absence of a formal affiliate. Wayne: Need to establish criteria regarding what we're going to be doing in the future, including in relation to the TSC.
- Going back to FHIR IGs: one first step could be quality criteria for US realm IGs. Issue is larger than FHIR IGs.
- ACTION: Anne to ask Dave if he can generate a report regarding what has been approved by US Realm from Project Insight - perhaps last 1-3 years sorted by family and date.
- Who is providing coordination among those IGs?
- Do we want to develop a list of principles for developing US Realm FHIR IGs?
- Reuse us-core
- Follow us realm extension development process
- Quality criteria (see example SDWG use for C-CDA)
- Where is quality criteria applied? Calvin: Is it FMG?
- Payer community representation on US Realm Steering Committee
- WGM agenda:
- Scope of US core
- Review list of US realm IGs that we should track
- Principles for developing US realm FHIR IGs
- Adjourned at 2:00 pm Eastern
Meeting Outcomes
| Actions
|
Next Meeting/Preliminary Agenda Items
|
© 2017 Health Level Seven® International. All rights reserved
